Commenting on California’s Prop 71 to fund stem cell research, my blogging colleague David Appell makes an excellent point about stem cells and Alzheimer’s, but he may be overstating the case a bit. An increasingly frequent–and legitimate–criticism of proponents of embryonic stem cell research is their tendency to link the cells with a treatment for Alzheimer’s (and tie such research to a legacy for President Reagan). However, as researchers point out, even if stem cells do not pan out as a therapy for Alzheimer’s, studies using the cells will still help patients by increasing our understanding of the disease. Such research could even lead to a new drug or other treatment that doesn’t use ES cells.
Singling out the tenuous Alzheimer’s link as a tactic being used to “sell” California voters on stem cells strikes me as a bit disingenuous. As David notes, there are at least 70 diseases, many of them common, such as diabetes and heart disease, that might be treated with stem cells. And there are countless others, such as Alzheimer’s and almost any form of cancer, that could be better understood through research using embryonic stem cells (as well as adult stem cells). It is indeed better to be up front with voters–about both the limits and the incredible potential of research on all types of stem cells.
10 Breakthrough Technologies 2024
Every year, we look for promising technologies poised to have a real impact on the world. Here are the advances that we think matter most right now.
Scientists are finding signals of long covid in blood. They could lead to new treatments.
Faults in a certain part of the immune system might be at the root of some long covid cases, new research suggests.
AI for everything: 10 Breakthrough Technologies 2024
Generative AI tools like ChatGPT reached mass adoption in record time, and reset the course of an entire industry.
What’s next for AI in 2024
Our writers look at the four hot trends to watch out for this year
Get the latest updates from
MIT Technology Review
Discover special offers, top stories, upcoming events, and more.